ArticleFrontiers in oncology2023

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.

Waleed Kian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.